Enliven Therapeutics (ELVN) investor relations material

Executive summary

• Focused on developing small molecule therapeutics, with ELVN-001 as the lead candidate in clinical trials for chronic myeloid leukemia (CML); development of ELVN-002 discontinued to prioritize ELVN-001 advancement.

• Positive initial Phase 1b data for ELVN-001 in CML supports its potential as a best-in-class ATP-competitive inhibitor.

• Enrollment ongoing in the 80 mg daily expansion cohort for ELVN-001 in previously treated CML, with Phase 1 data update expected mid-2026 and Phase 3 ENABLE-2 pivotal trial initiation planned for H2 2026.

• No products approved or revenue generated; operations funded by equity offerings, private placements, and at-the-market sales.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $452.4 million as of March 31, 2026, providing runway into H1 2029.

• Q1 2026 research and development expenses were $20.7 million, down from $24.9 million in Q1 2025, mainly due to discontinuation of ELVN-002.

• General and administrative expenses increased slightly to $7.1 million from $6.8 million year-over-year.

• Net loss for Q1 2026 was $23.6 million, with net loss per share (basic and diluted) at $(0.38), compared to $(0.57) in Q1 2025.

• Other income rose to $4.2 million from $3.1 million, driven by higher interest income.

Outlook and guidance

• Cash, cash equivalents, and marketable securities expected to fund operations for at least the next 12 months and potentially into H1 2029.

• Additional Phase 1 data from ENABLE trial to be presented mid-2026; regulatory interactions with FDA on dose selection and Phase 3 design expected in 2026.

• Anticipates increased expenses as ELVN-001 advances into pivotal trials and as pipeline expands.

• No meaningful revenue expected until regulatory approval and commercialization of a product candidate.